Schering Gene Therapy Terminal Population Supports Trial Continuation

The extremely ill patient population in Schering-Plough's study of SCH 58500 adenoviral vector-based gene therapy is one factor supporting continued enrollment in its liver cancer studies, the company told NIH's Recombinant DNA Advisory Committee Dec. 8.